Drugs / ASP2409
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02171143 | Apr 2012 → Apr 2014 | rheumatoid arthritis | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP2409 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02171143 ↗ |
| Action | Inhibit | “A Phase 1 Dose-Escalation Study of ASP2409, a Selective T-Cell Costimulation Inhibitor, in Stable Rheumatoid Arthritis Patients on Methotrexate Therapy.” PMID 27310327 ↗ Jan 2016 |
| Modality | Protein / enzyme biologic | “ASP2409 represents a new class of CTLA4-Ig molecules with higher binding avidity and selectivity to CD86.” PMID 27310327 ↗ Jan 2016 |
| Route | Intravenous | “ASP2409 showed nonlinear PK over the dose range of 0.01 to 3.0 mg/kg following a single intravenous administration, indicating target-mediated drug disposition.” PMID 27310327 ↗ Jan 2016 |
| Target | CD86 | “ASP2409 represents a new class of CTLA4-Ig molecules with higher binding avidity and selectivity to CD86.” PMID 27310327 ↗ Jan 2016 |